What can be done? The single most important step towards parity in PRS accuracy is by vastly increasing the diversity of participants included and analyzed in genetic studies, which will improve utility for all and most rapidly for underrepresented groups. Regulatory protections against genetic discrimination are necessary to accompany calls for more diverse studies; while some already exist in the U.S., including for health insurance and employment opportunities via the Genetic Information Nondiscrimination Act (GINA), stronger protections in these and other areas globally will be particularly important for minorities and/or marginalized groups. An equal investment in GWAS across all major ancestries and global populations is the most obvious solution to generate a substrate for equally informative risk scores but is not likely to occur any time soon absent a dramatic priority shift given the current imbalance and stalled diversifying progress over the last five years (Figure 1, Supplementary Figure 1). While it may be challenging or in some cases infeasible to acquire sample sizes large enough for PRS to be equally informative in all populations, some much-needed efforts towards increasing
